|Bid||5.05 x 1100|
|Ask||5.50 x 3000|
|Day's range||5.23 - 5.45|
|52-week range||4.28 - 10.05|
|Beta (5Y monthly)||0.69|
|PE ratio (TTM)||N/A|
|Earnings date||03 Nov 2021 - 08 Nov 2021|
|Forward dividend & yield||N/A (N/A)|
|1y target est||13.14|
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
With me today are Dr. Sean McCarthy, CytomX's President, Chief Executive Officer and Chairman; Dr Amy Peterson, Chief Development Officer; and Carlos Campoy, Chief Financial Officer. Earlier today, we issued a press release that includes a summary of our second quarter 2021 financial results and highlights the important progress we made during the quarter.
CytomX Therapeutics (CTMX) delivered earnings and revenue surprises of -15.38% and -10.16%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?